Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16566170 | 0.87 | ALDH1A1 (0.50) | ALDH1A1HPGDGAAALOX12L3MBTL1 | |
| SCHEMBL3485977 | 0.81 | ALDH1A1 (0.58) | ALDH1A1GAAMAPTKDM4ELMNA | |
| SCHEMBL774049 | 0.81 | ALDH1A1 (0.58) | ALDH1A1GAAMAPTKDM4ELMNA | |
| SCHEMBL14821834 | 0.80 | ALDH1A1 (0.61) | ALDH1A1HPGDGAAALOX12MAPT | |
| SCHEMBL20375597 | 0.79 | MAPT (0.42) | ALDH1A1MAPTLMNAADAM17HTT | |
| SCHEMBL13057567 | 0.79 | ALDH1A1 (0.51) | ALDH1A1HPGDGAAALOX12L3MBTL1 | |
| SCHEMBL16450893 | 0.79 | HSP90AA1 (0.59) | ALDH1A1HPGDGAAALOX12L3MBTL1 | |
| SCHEMBL11252258 | 0.79 | USP2 (0.47) | ALDH1A1GAAALOX12MAPTLMNA | |
| SCHEMBL13478303 | 0.79 | L3MBTL1 (0.47) | ALDH1A1HPGDGAAALOX12L3MBTL1 | |
| SCHEMBL12235539 | 0.79 | HSP90AA1 (0.59) | ALDH1A1HPGDGAAALOX12L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | MERCK PATENT GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
| EP-1379502-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002083640-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GMBH (DE) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | CHRNA1, CHRNA2, CHRNA10 | ALDH1A1 850/4885HPGD 2110/4885GAA 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.